Every year, promising drug candidates are sidelined not because of their science, but because of avoidable administrative and technical gaps. A Refuse-to-File (RTF) action is more than a clerical error; it is a strategic catastrophe that can delay market entry by over 400 days and cost millions in lost opportunity and remediation.

The FDA has recently pulled back the curtain, releasing the internal CDER Filing Checklists used by reviewers to judge your submission in the first 60 days. Join us for an intensive webinar where we translate these “internal answer keys” into a high-stakes roadmap for your next NDA or BLA submission.

Overview: Navigating the 60-Day Filing Window

The filing stage is the most vulnerable period of the drug development lifecycle. In these first 60 days, the FDA isn’t looking at your drug’s efficacy; they are looking for reasons to say “No.”

This webinar provides a deep-dive retrospective analysis of the FDA’s current filing expectations. We move beyond the basic regulations of 21 CFR 314.101 to examine the granular, discipline-specific checklists that CDER reviewers use to evaluate Clinical, Non-Clinical, and CMC data. Participants will learn how to shift from a “submission mindset”—simply getting the document out the door—to a “filing-ready mindset” that anticipates and neutralizes every potential red flag.

Detailed Topics to Be Covered

1. The Anatomy of an RTF: Why Submissions Fail

• The 426-Day Penalty: Breaking down the financial and operational impact of a filing rejection.
• Administrative vs. Scientific: Distinguishing between “potentially easily correctable” deficiencies and “significant flaws” that trigger an immediate RTF.

2. Decoding the CDER Internal Checklists

• CMC Integrity: Identifying the manufacturing data gaps that consistently trigger rejections in the modern regulatory climate.
• Clinical & Statistical Mapping: Ensuring that datasets and case report forms (CRFs) align perfectly with the FDA’s automated screening tools.
• The eCTD 4.0 Standard: Technical requirements and metadata accuracy that can make or break a digital submission.

3. The “Mock Filing” Framework

• Internal Due Diligence: How to conduct a rigorous root cause evaluation of your own dossier 18 months before submission.
• The 18-Month Runway: Establishing a cross-functional timeline that synchronizes quality, clinical, and regulatory streams.

4. High-Stakes Communication Strategies

• Navigating the 60-Day Window: Best practices for responding to Information Requests (IRs) during the initial filing review.
• The Power of Type A Meetings: When and how to use formal meetings to resolve technical hurdles before the clock starts.

Why You Should Attend

In the current regulatory landscape, “good enough” is a recipe for rejection. This webinar isn’t just about compliance; it’s about competitive advantage.

• Gain the “Reviewer’s Perspective”: See exactly what the FDA sees when they open your eCTD for the first time.
• Reduce Time-to-Market: Learn the strategies that lead to “First-Cycle Approval” by eliminating the technical errors that lead to RTFs.
• Master Risk-Based Negotiation: Understand which deficiencies are negotiable and which require a complete resubmission.
• Implement Practical Tools: Walk away with a framework for conducting your own internal filing reviews using the FDA’s own criteria.

Who Will Benefit

This session is designed specifically for middle and senior-level professionals in the drug and medical device industries who are responsible for the integrity and success of FDA submissions:

• Regulatory Affairs Directors & Managers: To sharpen submission strategy and oversight.
• Quality Assurance & Quality Control Professionals: To ensure CMC and manufacturing data meet filing-ready standards.
• Clinical Operations Leaders: To bridge the gap between study completion and data submission.
• Technical Writers & eCTD Publishers: To master the technical nuances of the modern filing checklist.
• Consultants & Advisory Boards: Providing high-level guidance for IND, NDA, and BLA preparation.